Assessing AnaptysBio (ANAB) Valuation After New Share Buyback Plan And Canceled Equity Offering

Why the new capital plan matters for AnaptysBio (ANAB)

AnaptysBio (ANAB) has put capital allocation in the spotlight, authorizing up to US$100 million in share repurchases while pulling its planned at the market follow on equity offerings.

For you as an investor, that combination removes the immediate prospect of new share issuance and signals management is opting to return capital through buybacks rather than raise fresh equity at current levels.

See our latest analysis for AnaptysBio.

These capital moves sit against a share price of US$57.68, with a 90 day share price return of 33.52% and a 1 year total shareholder return of 211.62%. This suggests momentum has recently been building alongside the buyback news, board refresh and upcoming First Tracks Bio spin off.

If this kind of biotech activity has your attention, it could be a good moment to see what else is moving in healthcare by checking the 36 healthcare AI stocks

The question now is straightforward. With the shares at US$57.68 and trading at a reported intrinsic discount of around 87%, are you looking at an undervalued biotech, or has the market already priced in what comes next?

Preferred Price-to-Sales of 7.1x: Is it justified?

On a P/S basis, AnaptysBio trades at 7.1x, which sits below both the US Biotechs industry average of 11.1x and the peer group average of 10.2x.

The P/S ratio compares the company’s market value to its revenue, which can be useful for loss making biotechs where profits are not yet a guide. With revenue of $234.6 million and the business still reporting a net loss of $13.2 million, investors are effectively paying more for current sales than the estimated fair P/S ratio suggests, but less than for many sector peers.

Analysts posting a fair P/S estimate of 4.1x imply a level the market could move toward if sentiment or growth expectations cool. At the same time, the current 7.1x multiple is meaningfully lower than the 11.1x industry average and 10.2x peer average. This points to the market assigning AnaptysBio a discount to many comparable biotech names despite its recent share price gains.

Explore the SWS fair ratio for AnaptysBio

Result: Price-to-sales of 7.1x (ABOUT RIGHT)

However, there are still clear risks, including its clinical stage focus with ongoing net losses, and the possibility that sentiment could shift if revenue growth or trial milestones disappoint.

Find out about the key risks to this AnaptysBio narrative.

Another view from our DCF model

While the current P/S of 7.1x looks lower than many biotech peers, the SWS DCF model tells a very different story. At a share price of $57.68, AnaptysBio is trading around 87% below that model’s fair value estimate of $459.45, which is a very large gap.

That kind of disconnect between a revenue based multiple and a future cash flow based estimate can cut both ways. It can point to room for rerating, or to optimistic cash flow assumptions that may never be met. As an investor, the key question is which signal you choose to put more weight on.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AnaptysBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether the optimism and caution in this story line up with your own view? You can take a closer look at the full picture by checking the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you want to keep building on your research, now is a great time to scan the market for other potential opportunities before they move out of reach.

• Spot potential value opportunities early by checking stocks that show strong quality traits and attractive pricing using the 58 high quality undervalued stocks.
• Secure potential income ideas by reviewing companies that combine higher yields with a focus on resilience through the 13 dividend fortresses.
• Reduce portfolio stress by focusing on companies with sturdier finances and fundamentals highlighted in the solid balance sheet and fundamentals stocks screener (40 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com